The Global Market for Immune
Thrombocytopenia is projected to surpass a valuation of USD 2,300 Mn by 2023,
reflecting a compound annual growth rate of 5.78% between 2018 and 2023. Rising
prevalence of immune thrombocytopenia (ITP) worldwide has fueled the demand for
ITP therapeutics. Increased government effort to improve healthcare
infrastructure in countries such as India, China and Brazil has reflected
favorably on the global ITP market. In addition, increased focus on development
of novel drugs and therapeutics is also having a positive impact on the market.
Autoimmune diseases, chronic infections, medications, pregnancy, and certain
cancers are common secondary triggers of ITP.
The MRFR report includes a thorough assessment of
the global immune thrombocytopenia (ITP) market along with a five-year
(2018-2023) revenue forecast. The report includes a discussion on several key
market elements. The scope of the discussion also covers different ITP
treatments that are currently available such as intravenous immunoglobulins,
thrombopoietin receptor agonists and corticosteroids among other. It also
covers revenue analysis of major end-users of immune thrombocytopenia, which
covers hospitals and clinics, specialty centers, and research and academic
institutes. A detail analysis of the various sub-markets across key
region of the world is also available in the report.
Historical market trends, market dynamics,
forecast, market value by region as well as by segmentation, country-level
analysis for each market segment, key player’s market share analysis and market
factor analysis which covers supply chain and Porter’s five forces analysis of
the market
Competitive Landscape:
CSL Limited, Amgen Inc., F.Hoffmann-La Roche Ltd.,
Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Shionogi Inc., Dova
Pharmaceuticals, Novartis AG, Jiangsu Hengrui Pharmaceutical Co., Ltd., Shire
and Ligand Pharmaceuticals, Inc.
Research Methodology:
The research methodology envelops the range and
depth of markets and industries that ensures the best outlooks are presented.
The methodology successfully combines primary and secondary research methods to
present exclusive and pertinent content that can aid in well-versed decision
making. The different advances in markets are uniquely included in the reports
by employing top-down and bottom-up approaches. Insightful data, advantageous
scenarios, and outline of the emerging markets make for a complete and astute
guide into the beat of the market. Also, the consistency levels of our reports
offer our users adept intelligence that can shape the base of strategies they
devise to gain the preferred market portions and hold & enhance their
current customer base in several geographies.
Segmental Analysis:
The
segmental analysis of the global ITP market is based on type, treatment,
end-user and region. By type, the market has been segmented into chronic immune
thrombocytopenia and acute immune thrombocytopenia. In 2017, the chronic immune
thrombocytopenia segment for 85% share of the global market. During the
forecast period, the segment is projected to witness a CAGR of 5.94% and reach
a valuation of USD 2,036.9 Mn. This can be attributed to factors such as rising
incidence rates, approval of targeted treatments, increase in risk factors, use
of prior medications, and increase occurrence of secondary hematological
disorders.
On
the basis of the treatment, the market has been segmented into intravenous
immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and
others. In 2017, the corticosteroids
segmented represented 40% share of the global ITP market in terms of value. The
segment is likely to surge at a CAGR of 5.57% during the assessment period.
Corticosteroids are a class of steroid hormones that are commonly used in ITP
therapies.
On
the basis of end-user, the market has been segmented into hospitals and
clinics, specialty centers, research and academic institutes, and others. The
hospitals & clinic segment currently commands for close to 38% market share
and is projected to capture an impressive CAGR of 6.22% during the review
period.
Regional Outlook:
On
the basis of region, the Global ITP market is segmented into Americas, Europe,
Asia Pacific (APAC) and the Middle East & Africa (MEA). Of these, the
Americas accounted for 43.3% market share in 2017. The Americas is expected to
spearhead the global ITP market throughout the assessment period. This is
primarily owing to the increasing prevalence rates coupled with the
availability of treatment options and presence effective reimbursement
policies. According to the National Organization for Rare Disorders (NORD), the
prevalence of immune thrombocytopenia among adults in the US is estimated to be
3.3 per 100,000 adults/year. In addition, Americas is expected to remain an
important market for ITP during the assessment period. Americas is followed by
Europe and Asia-Pacific respectively. In Europe, factors such as favorable
government policies and high healthcare expenditure is supporting the growth of
the market. At the same time, presence of advanced healthcare infrastructure is
providing an impetus to the market in Europe. The region is likely to remain
its second spot over 2023. In Asia Pacific, increased efforts towards improving
healthcare services and rising level of awareness among people is anticipated
to drive the market’s growth in APAC in the forthcoming years.
Browse
Complete 85 Pages Premium Research Report Enabled with Respective Tables and
Figures @ https://www.marketresearchfuture.com/reports/immune-thrombocytopenia-itp-market-6996
Detailed Table
of Contents for Immune Thrombocytopenia (ITP)
Market
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6
Technology Trends & Assessment
...TOC
Continued!
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment